154 related articles for article (PubMed ID: 32739767)
1. Timing of sentinel node biopsy independently predicts disease-free and overall survival in clinical stage I-II melanoma patients: A multicentre study of the Italian Melanoma Intergroup (IMI).
Mandalà M; Galli F; Patuzzo R; Maurichi A; Mocellin S; Rossi CR; Rulli E; Montesco M; Quaglino P; Caliendo V; De Giorgi V; Merelli B; Caracò C; Piazzalunga D; Labianca A; Ribero S; Senetta R; Gianatti A; Valeri B; Massi D; Ascierto PA; Santinami M;
Eur J Cancer; 2020 Sep; 137():30-39. PubMed ID: 32739767
[TBL] [Abstract][Full Text] [Related]
2. Effects of time interval between primary melanoma excision and sentinel node biopsy on positivity rate and survival.
Oude Ophuis CM; van Akkooi AC; Rutkowski P; Voit CA; Stepniak J; Erler NS; Eggermont AM; Wouters MW; Grünhagen DJ; Verhoef CK
Eur J Cancer; 2016 Nov; 67():164-173. PubMed ID: 27669503
[TBL] [Abstract][Full Text] [Related]
3. The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients - An EORTC Melanoma Group study.
Oude Ophuis CM; Verhoef C; Rutkowski P; Powell BW; van der Hage JA; van Leeuwen PA; Voit CA; Testori A; Robert C; Hoekstra HJ; Grünhagen DJ; Eggermont AM; van Akkooi AC
Eur J Surg Oncol; 2016 Dec; 42(12):1906-1913. PubMed ID: 27266406
[TBL] [Abstract][Full Text] [Related]
4. Time interval between diagnostic excision-biopsy of a primary melanoma and sentinel node biopsy: effects on the sentinel node positivity rate and survival outcomes.
El Sharouni MA; Scolyer RA; van Gils CH; Ch'ng S; Nieweg OE; Pennington TE; Saw RPM; Shannon K; Spillane A; Stretch J; Witkamp AJ; Sigurdsson V; Thompson JF; van Diest PJ; Lo SN
Eur J Cancer; 2022 May; 167():123-132. PubMed ID: 35256245
[TBL] [Abstract][Full Text] [Related]
5. Acral lentiginous melanoma histotype predicts outcome in clinical stage I-II melanoma patients: an International multicenter study.
Mandalà M; Rutkowski P; Galli F; Patuzzo R; De Giorgi V; Rulli E; Gianatti A; Valeri B; Merelli B; Szumera-Ciećkiewicz A; Massi D; Maurichi A; Teterycz P; Santinami M
ESMO Open; 2022 Jun; 7(3):100469. PubMed ID: 35421840
[TBL] [Abstract][Full Text] [Related]
6. The prognostic impact of the extent of ulceration in patients with clinical stage I-II melanoma: a multicentre study of the Italian Melanoma Intergroup (IMI).
Portelli F; Galli F; Cattaneo L; Cossa M; De Giorgi V; Forte G; Fraternali Orcioni G; Gianatti A; Indini A; Labianca A; Maurichi A; Merelli B; Montesco MC; Occelli M; Patuzzo R; Piazzalunga D; Pigozzo J; Quaglino P; Ribero S; Salvatori R; Saraggi D; Sena P; Senetta R; Valeri B; Tanaka M; Fukayama M; Palmieri G; Mandalà M; Massi D;
Br J Dermatol; 2021 Feb; 184(2):281-288. PubMed ID: 32282932
[TBL] [Abstract][Full Text] [Related]
7. Predicting sentinel and residual lymph node basin disease after sentinel lymph node biopsy for melanoma.
Wagner JD; Gordon MS; Chuang TY; Coleman JJ; Hayes JT; Jung SH; Love C
Cancer; 2000 Jul; 89(2):453-62. PubMed ID: 10918179
[TBL] [Abstract][Full Text] [Related]
8. Incomplete sentinel node biopsy is not clearly related to survival or regional recurrence in cutaneous melanoma patients.
Lee NC; Spillane AJ; Pang TC; Haydu LE; Uren RF
Ann Surg Oncol; 2012 Jan; 19(1):280-6. PubMed ID: 21833669
[TBL] [Abstract][Full Text] [Related]
9. The impact of lymphoscintigraphy technique on the outcome of sentinel node biopsy in 1,313 patients with cutaneous melanoma: an Italian Multicentric Study (SOLISM-IMI).
Rossi CR; De Salvo GL; Trifirò G; Mocellin S; Landi G; Macripò G; Carcoforo P; Ricotti G; Giudice G; Picciotto F; Donner D; Di Filippo F; Montesco MC; Casara D; Schiavon M; Foletto M; Baldini F; Testori A
J Nucl Med; 2006 Feb; 47(2):234-41. PubMed ID: 16455628
[TBL] [Abstract][Full Text] [Related]
10. The prognostic significance of non-sentinel lymph node metastasis in cutaneous and acral melanoma patients-A multicenter retrospective study.
Sun W; Xu Y; Yang J; Liao Z; Li T; Huang K; Patel P; Yan W; Chen Y
Cancer Commun (Lond); 2020 Nov; 40(11):586-597. PubMed ID: 33025763
[TBL] [Abstract][Full Text] [Related]
11. Timing of completion lymphadenectomy after positive sentinel node biopsy in patients with melanoma.
Oude Ophuis CM; van Akkooi AC; Rutkowski P; Powell WE; Robert C; Testori A; van Leeuwen BL; Siegel P; Eggermont AM; Verhoef C; Grünhagen DJ
Br J Surg; 2017 May; 104(6):726-733. PubMed ID: 28218385
[TBL] [Abstract][Full Text] [Related]
12. Sentinel node biopsy (SNB) in malignant melanoma as same day procedure vs delayed procedure: clinical and economic outcome.
Rødgaard JC; Kramer S; Stolle LB
J Plast Surg Hand Surg; 2014 Aug; 48(4):265-9. PubMed ID: 24328901
[TBL] [Abstract][Full Text] [Related]
13. Clinical considerations on sentinel node biopsy in melanoma from an Italian multicentric study on 1,313 patients (SOLISM-IMI).
Testori A; De Salvo GL; Montesco MC; Trifirò G; Mocellin S; Landi G; Macripò G; Carcoforo P; Ricotti G; Giudice G; Picciotto F; Donner D; Di Filippo F; Soteldo J; Casara D; Schiavon M; Vecchiato A; Pasquali S; Baldini F; Mazzarol G; Rossi CR;
Ann Surg Oncol; 2009 Jul; 16(7):2018-27. PubMed ID: 19132446
[TBL] [Abstract][Full Text] [Related]
14. Sentinel node biopsy provides more accurate staging than elective lymph node dissection in patients with cutaneous melanoma.
Doubrovsky A; De Wilt JH; Scolyer RA; McCarthy WH; Thompson JF
Ann Surg Oncol; 2004 Sep; 11(9):829-36. PubMed ID: 15313732
[TBL] [Abstract][Full Text] [Related]
15. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of sentinel node biopsy in 327 prospective melanoma patients from a single institution.
Roulin D; Matter M; Bady P; Liénard D; Gugerli O; Boubaker A; Bron L; Lejeune FJ
Eur J Surg Oncol; 2008 Jun; 34(6):673-9. PubMed ID: 17825518
[TBL] [Abstract][Full Text] [Related]
17. BRAF immunohistochemistry predicts sentinel lymph node involvement in intermediate thickness melanomas.
Manninen AA; Gardberg M; Juteau S; Ilmonen S; Jukonen J; Andersson N; Carpén O
PLoS One; 2019; 14(4):e0216043. PubMed ID: 31039200
[TBL] [Abstract][Full Text] [Related]
18. Ulceration as a predictive marker for response to adjuvant interferon therapy in melanoma.
McMasters KM; Edwards MJ; Ross MI; Reintgen DS; Martin RC; Urist MM; Noyes RD; Sussman JJ; Stromberg AJ; Scoggins CR
Ann Surg; 2010 Sep; 252(3):460-5; discussion 465-6. PubMed ID: 20739846
[TBL] [Abstract][Full Text] [Related]
19. Sentinel Node Biopsy Alone or With Axillary Dissection in Breast Cancer Patients After Primary Chemotherapy: Long-Term Results of a Prospective Interventional Study.
Martelli G; Barretta F; Miceli R; Folli S; Maugeri I; Listorti C; Scaperrotta G; Baili P; Pruneri G; Capri G; Ferraris C
Ann Surg; 2022 Nov; 276(5):e544-e552. PubMed ID: 33065651
[TBL] [Abstract][Full Text] [Related]
20. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
